Silo Pharma
Silo Pharma is a developmental-stage biopharmaceutical company (Nasdaq: SILO) developing intranasal and implant CNS therapeutics for PTSD, fibromyalgia, Alzheimer's, and TBI through the 505(b)(2) pathway, with core IP licensed from Columbia University. It also operates a newly acquired AI agent subsidiary, QwikAgents, targeting the consumer/SMB market via subscription.
- Company typePublic
- Founded2020
- HeadquartersEnglewood Cliffs, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Silo Pharma does
Silo Pharma, Inc. is a developmental-stage biopharmaceutical company incorporated in Florida in 2020 and publicly traded on the Nasdaq Capital Market under the ticker SILO. The company is developing novel therapeutics for underserved central nervous system conditions, with a pipeline consisting of SPC-15 (a pre-IND intranasal serotonin 4 receptor agonist for prophylactic PTSD treatment), SP-26 (a subcutaneous time-released ketamine implant for fibromyalgia and chronic pain, preclinical), SPC-14 (a preclinical Alzheimer's candidate), and a recently filed provisional patent for ibogaine-based therapeutics targeting traumatic brain injury. Silo pursues the streamlined 505(b)(2) FDA approval pathway and licenses core intellectual property exclusively from Columbia University, with granted US Patent No. 12,239,614 (March 2025), a Japan Patent Office Notice of Allowance, and an intent-to-grant from the European Patent Office.
The company's technology platform centers on a patented intranasal nose-to-brain drug delivery system designed to bypass the blood-brain barrier, providing direct CNS drug concentration with optimized safety. In April 2026, Silo Pharma expanded beyond pure-play biopharma by acquiring the assets of Qwikagents.ai and forming a wholly-owned AI subsidiary that offers personal AI agents — accessible via Telegram, Slack, and Discord — on a subscription basis at $14-72 per month, with initial support for the OpenClaw agent framework. The company has also launched a Digital Assets Treasury Program involving cryptocurrency holdings and tokenized real-world assets on the Solana blockchain.
Silo Pharma is currently pre-revenue from pharmaceutical operations, reporting only $0.02M in Q1 2026 revenue with a deeply negative net margin of 5,870.83%. The company has raised approximately $8.6M through four registered direct and public offerings in 2024-2025 via H.C. Wainwright & Co. as exclusive placement agent. Following a 1-for-15 reverse stock split effective June 2, 2026, the company had approximately 1.084 million shares outstanding and a market capitalization of approximately $6.96M, with a current ratio of 9.65 indicating a cash-rich balance sheet. Go-to-market for pharmaceuticals is entirely pre-commercial; marketing and distribution are oriented toward institutional investors through press releases, the H.C. Wainwright Annual Global Investment Conference, and an investor relations website. Leadership includes founder and CEO Eric Weisblum, CFO Daniel Ryweck (CPA), and VP of R&D Dr. James Kuo (former Pfizer and HealthCare Ventures executive).
Silo Pharma firmographics
Firmographics- Name
- Silo Pharma
- Legal name
- Silo Pharma, Inc.
- Website
- https://silopharma.com
- Company type
- Public
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Silo Pharma is a developmental-stage biopharmaceutical company (Nasdaq: SILO) developing intranasal and implant CNS therapeutics for PTSD, fibromyalgia, Alzheimer's, and TBI through the 505(b)(2) pathway, with core IP licensed from Columbia University. It also operates a newly acquired AI agent subsidiary, QwikAgents, targeting the consumer/SMB market via subscription.
- Ownership category
- akta.pro rank
Silo Pharma industry classification
Industry- Product category
- CNS Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)
Keywords
Where Silo Pharma is headquartered
LocationHeadquarters
- HQ city
- Englewood Cliffs
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Silo Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Development and Licensing: As a developmental-stage biopharmaceutical company, Silo Pharma does not currently generate revenue. The company is focused on developing novel therapeutics for underserved conditions including PTSD, fibromyalgia, and Alzheimer's disease through the 505(b)(2) regulatory pathway. Revenue would potentially be generated through product sales, licensing deals, or partnerships upon successful FDA approval and commercialization.
- AI Agent Services (QwikAgents): Silo Pharma launched an AI subsidiary to operate the Qwikagents.ai platform, targeting the AI agent market projected to reach $47-53 billion by 2030 with 43-50% annual growth. AI agents are offered at $14-72/month, creating a new revenue stream for the company alongside its pharmaceutical operations.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Personal AI Agent Subscription |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Silo Pharma product offering
Product offeringCore offering
Silo Pharma is a developmental-stage biopharmaceutical company developing novel therapeutics for underserved CNS conditions, including the lead candidate SPC-15, an intranasal 5-HT4 receptor agonist for prophylactic PTSD treatment, the SP-26 ketamine implant for fibromyalgia and chronic pain, and SPC-14 for Alzheimer's disease. The company also operates a QwikAgents AI subsidiary offering subscription-based personal AI agents accessible through messaging platforms. All pharmaceutical assets are currently pre-commercial or pre-IND.
Product overview
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company with two distinct operational segments. The biopharmaceutical division centers on a pipeline of novel therapeutic compounds including SPC-15 (intranasal 5-HT4 receptor agonist for PTSD, pre-IND), SP-26 (ketamine implant for fibromyalgia, preclinical), and SPC-14 (Alzheimer's treatment, preclinical), developed in collaboration with academic institutions like Columbia University. The company also operates QwikAgents, an AI subsidiary offering personal AI agents accessible through Telegram, Slack, and Discord, positioning itself as a provider of digital workforce solutions. Additionally, Silo Pharma maintains a digital assets treasury program investing in cryptocurrency and tokenized real-world assets on the Solana blockchain.
Differentiator
Problem solved
Functional benefit
Brands
- QwikAgents: AI subsidiary platform offering personal AI agents that work 24/7, supporting various AI agent frameworks including OpenClaw, with subscription plans ranging from $14-72/month.
Products and services
- SPC-15 Novel intranasal serotonin 4 (5-HT4) receptor agonist designed as a prophylactic treatment for stress-induced affective disorders including PTSD. Features a patented nose-to-brain delivery system that bypasses the blood-brain barrier, providing direct and heightened drug concentration in the brain with faster therapeutic onset and optimized patient safety. Currently in pre-IND stage.
- SP-26
Quantifiable outcome
- SPC-15 maintained stability through 9 months of real-time testing under IND-enabling conditions
- +3 more outcomes
Companies that use Silo Pharma
Customer profileSegments4 records
Ideal customer profiles2 records
Silo Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability2 records
Feature4 records
Silo Pharma partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Qwikagents.aicoreSilo Pharma acquired assets of Qwikagents.ai and formed a new AI subsidiary to operate the platform. The AI agent platform enables personal AI agents that work 24/7 through apps like Telegram, Slack, or Discord. The company cited market projections estimating the AI agent sector will reach $47-53 billion by 2030 with 43-50% annual growth. The new subsidiary is expected to create an additional revenue stream.
- AllucentcoreSilo Pharma selected Allucent, a global clinical research organization, to support the preparation and planned submission of an Investigational New Drug application to the FDA for SPC-15, an intranasal prophylactic treatment for PTSD. The company expects to submit the IND in 2026 and commence first-in-human Phase 1 clinical trials following FDA approval. GLP toxicology and drug-device study data was anticipated in early 2026.
- Columbia UniversitycoreExclusive licensing agreement with Columbia University for intellectual property related to SPC-15 (serotonin 4 receptor agonist for stress-related disorders) and other therapeutic candidates. The licensing agreement enables Silo Pharma to pursue the 505(b)(2) regulatory pathway for faster approval. Columbia University's CELA (presumably Center for Experimental Drugs and Therapeutics or similar) collaboration supports drug development.
Scale indicators18 records
Recent moves7 records
Expansion highlights6 records
Silo Pharma competitors and assessment
Company assessmentDirect peers
- ATAI Life Sciences: Clinical-stage biopharma developing psychedelic and non-psychedelic therapies for mental health disorders. Direct peer in psychedelic CNS drug development with a portfolio approach across multiple CNS indications similar to Silo's.
- GH Research: Clinical-stage biopharma developing novel psychedelic therapies for psychiatric and neurological disorders. Directly comparable as a small-cap CNS/psychedelic-focused developer with similar regulatory and clinical milestones.
- Cybin: Clinical-stage psychedelic therapeutics company developing deuterated tryptamine-based therapies for mental health conditions. Direct peer in psychedelic CNS drug development with comparable pipeline scope and target indications.
- Compass Pathways: Mental health care company developing psilocybin therapy for treatment-resistant depression. Direct peer in psychedelic CNS drug development with comparable regulatory pathway focus and clinical-stage pipeline.
- Mind Medicine (MindMed): Clinical-stage psychedelic CNS biopharma developing psychedelic-inspired therapies for mental health and CNS conditions. Directly comparable to Silo in pipeline category (CNS, psychedelic-adjacent) and target indications including anxiety/PTSD-like conditions, with a similarly small market cap and early clinical stage.
- Tonix Pharmaceuticals: Clinical-stage CNS biopharma developing therapies for PTSD, fibromyalgia, and CNS disorders. Direct peer in indication overlap (PTSD, fibromyalgia) and CNS development focus, with a small-cap profile similar to Silo's.
Broad incumbents
- Sage Therapeutics: Commercial-stage CNS biopharma with FDA-approved CNS therapies (Zulresso, Zurzuvae). Comparable in CNS/neurology focus and 505(b)-style regulatory navigation, but a more established player with commercial products and a broader pipeline.
- Acadia Pharmaceuticals: Commercial-stage CNS biopharma focused on neurological and psychiatric disorders including Parkinson's disease psychosis and Rett syndrome. Comparable in CNS therapeutic focus with a more mature commercial footprint than Silo.
Emerging players
- Bionomics Limited: Clinical-stage biopharma developing CNS therapies with a specific focus on PTSD and anxiety. Directly comparable in PTSD indication focus, with a small-cap clinical-stage profile similar to Silo's.
- Tryp Therapeutics: Clinical-stage psychedelic drug development company with overlapping CNS/psychedelic thesis and previously led by Dr. James Kuo (Silo's VP of R&D). Comparable in psychedelic CNS pipeline focus and stage.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Silo Pharma social profiles
Digital presenceSilo Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Silo Pharma leadership team
Management profileNumber of profiles
Profiles7 records
Silo Pharma subsidiaries and ownership
Company hierarchySubsidiaries1 record
Silo Pharma funding detail
Funding detailFunding overview
Funding rounds8 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Silo Pharma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Silo Pharma
What does Silo Pharma do?
Silo Pharma is a developmental-stage biopharmaceutical company developing novel therapeutics for underserved CNS conditions, including the lead candidate SPC-15, an intranasal 5-HT4 receptor agonist for prophylactic PTSD treatment, the SP-26 ketamine implant for fibromyalgia and chronic pain, and SPC-14 for Alzheimer's disease. The company also operates a QwikAgents AI subsidiary offering subscription-based personal AI agents accessible through messaging platforms. All pharmaceutical assets are currently pre-commercial or pre-IND.
Is Silo Pharma a public or private company?
Silo Pharma is a public company. It is classified as public and is currently operating.
When was Silo Pharma founded?
Silo Pharma was founded in 2020. It employs 11 to 50 people.
Where is Silo Pharma based?
Silo Pharma is headquartered in Englewood Cliffs, United States, in the North America region.
How does Silo Pharma make money?
Two revenue lines are on record. Pharmaceutical Development and Licensing is the primary driver. The others are AI Agent Services (QwikAgents).
Who are Silo Pharma's main competitors?
Direct peers on record are ATAI Life Sciences, GH Research, Cybin, Compass Pathways, Mind Medicine (MindMed) and Tonix Pharmaceuticals. Broad incumbents are Sage Therapeutics and Acadia Pharmaceuticals. Emerging players are Bionomics Limited and Tryp Therapeutics.
Does Silo Pharma have an API?
No public API is recorded for Silo Pharma.
What industry is Silo Pharma in?
Silo Pharma's product category is CNS Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.